Magnesium gunstig bij hartfalen

[bert]

2010 – Suppletie met magnesium heeft gunstige effecten voor patiënten met hartfalen, aldus onderzoekers van de Universiteit van Tel Aviv.

De wetenschappers onderzochten 32 hartfalenpatiënten met een normale magnesiumspiegel in het bloed. De helft van de groep kreeg gedurende vijf weken dagelijks een supplement met 300 mg magnesium (als magnesiumcitraat). De andere helft slikte geen magnesiumsupplement.

In de magnesiumgroep steeg de concentratie magnesium in het serum en de intracellulaire ruimten en verbeterde de heart rate variability (HRV; variatie in hartfrequentie) in vergelijking met de controlegroep.

Een tekort aan magnesium en een verminderde HRV komen vaak voor bij hartfalen. Beiden zijn gerelateerd aan een slechte prognose voor de patiënt. Magnesiumsuppletie zou deze prognose kunnen verbeteren.

Bron: ortho.nl en hun bron is deze:
http://www.ncbi.nlm.nih.gov/pubmed/19201586

Almoznino-Sarafian D, Sarafian G, [..], Gorelik O. Magnesium administration may improve heart rate variability in patients with heart failure. Nutr Metab Cardiovasc Dis 2009; 19(9):641-5

Magnesium administration may improve heart rate variability in patients with heart failure.

Almoznino-Sarafian D, Sarafian G, Berman S, Shteinshnaider M, Tzur I, Cohen N, Gorelik O.

Department of Internal Medicine F, Assaf Harofeh Medical Center (Affiliated to the Sackler School of Medicine, Tel Aviv University), Zerifin 70300, Israel. internal6@asaf.health.gov.il

Sanenvatting van de studie:
BACKGROUND AND AIM: Intracellular magnesium (icMg) depletion may coexist with normomagnesemia. (dwz bij een nog normale magnesiumwaarde in bloed (serum) kan er in de cellen toch al een tekort zijn!)

Mg deficiency (serum and/or intracellular) and decreased heart rate variability (HRV) are common in heart failure (HF). Since both are predictors of poor prognosis, it was of interest to evaluate the effect of Mg supplementation on HRV in patients with HF.

METHODS AND RESULTS: We investigated the effect of Mg administration on HRV in normomagnesemic patients with systolic HF.
HRV, serum Mg and icMg were determined before and after 5-week 300 mg/day Mg citrate treatment in 16 patients (group 1).
The control group included 16 Mg-non-treated HF patients (group 2).
HRV was determined by a non-linear dynamics analysis, derived from the chaos theory, which calculates HRV-correlation dimension (HRV-CD).

After 5 weeks, serum Mg (mmol/l) increased more significantly in group 1 (from 0.78+/-0.04 to 0.89+/-0.06, p<0.001), than in group 2 (from 0.79+/-0.07 to 0.84+/-0.06, p=0.042).
IcMg and HRV-CD increased significantly only in group 1 (from 59+/-7 to 66+/-9 mmol/g cell protein, p=0.025, and from 3.47+/-0.42 to 3.94+/-0.36, p<0.001, respectively).
In group 2, the differences in the respective parameters were 63+/-12 to 66+/-9 mmol/g cell protein (p=0.7) and 3.59+/-0.42 to 3.55+/-0.4 (p=0.8).

CONCLUSION: Mg administration to normomagnesemic patients with systolic HF increases serum Mg, icMg and HRV-CD. Increasing of HRV by Mg supplementation may prove beneficial to HF patients.

PMID: 19201586 [PubMed - indexed for MEDLINE]

[Lisa]

Nog een artikel over magnesium bij hartfalen: nu over het effect van magnesium- suppletie op het CRP (de bekende marker voor ontstekingen in het lichaam): Magnesium verlaagde het CRP bij mensen met hartfalen (die, in vergelijking met mensen zonder hartfalen, een hogere CRP waarde en een lager serum-magnesium hebben).

http://www.ncbi.nlm.nih.gov/pubmed/17479208

Eur J Nutr. 2007 Jun;46(4):230-7. .
Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?

Almoznino-Sarafian D, Berman S, Mor A, Shteinshnaider M, Gorelik O, Tzur I, Alon I, Modai D, Cohen N.

Dept. of Internal medicine F, Assaf Harofeh Medical Center, Zerifin 70300, Israel.
Abstract

BACKGROUND: Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF).

AIM OF THE STUDY: To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels.

METHODS: Serum Mg and CRP were evaluated in 68 patients with chronic systolic HF leading to hospital admission and 65 patients requiring hospitalization for other causes. Following 5 weeks, serum Mg, CRP and intracellular Mg were reevaluated in 17 HF patients after administration of oral Mg citrate 300 mg/day (group A), and 18 untreated HF patients (group B ).
In order to obtain Gaussian distribution, logarithmic transformation of CRP was performed.

RESULTS: Inverse correlation was found between serum Mg and log CRP (r = -0.28, P = 0.002).
Compared to controls, patients with HF demonstrated higher baseline CRP levels, independent of coexisting conditions, and lower serum Mg values.
Following Mg treatment, log CRP decreased from 1.4 +/- 0.4 to 0.8 +/- 0.3 in group A (P < 0.001). No significant changes in log CRP were demonstrable in group B. Serum Mg (mmol/l) rose significantly in group A (0.74 +/- 0.04-0.88 +/- 0.08, P < 0.001), and to a lesser extent in group B (0.82 +/- 0.08-0.88 +/- 0.08, P = 0.04). Intracellular Mg significantly increased only in Mg-treated group A (P = 0.01). CONCLUSIONS: Oral Mg supplementation to HF patients significantly attenuates blood levels of CRP, a biomarker of inflammation. Targeting the inflammatory cascade by Mg administration might prove a useful tool for improving the prognosis in HF. PMID: 17479208 [PubMed - indexed for MEDLINE]

[Auteur]

Berichten